To date, acetylcholinesterase inhibitors (AChEI) approved by the Food and Drug Administration (FDA) for the treatment of AD clinically majorly included taclin, donepezil, rivastigmine, and galantamine (Shaikh et al., 2014). Here, ACHE is linked to Alzheimer disease.